DLGAP5 and urinary bladder carcinoma: On the other hand, DLGAP5 interacts with the deubiquitinating enzyme USP11 to stabilize MYC protein, which in turn upregulates the expression of glycolysis-related genes in bladder cancer cells, forming a DLGAP5-USP11-MYC-positive feedback loop that enhances chemoresistance to gemcitabine in bladder cancer cells [106].